Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
Women diagnosed with early stage ovarian cancer may be considered for adjuvant therapy. Intraperitoneal chromic phosphate (P-32) is commonly used in these patients with few complications. A woman found to have early stage ovarian cancer was given intraperitoneal P-32 in the presence of a lingering pelvic infection, which is usually not mentioned as a contraindication to its use. Radiation damage to the small bowel and cecum developed as did damage to the ureter and bladder, which then required surgery.
McGowan
L
L
Department of Obstetrics and Gynecology, George Washington University, Washington, DC 20037.
D000328:Adult; D017608:Chromium Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000075202:Contraindications; D018291:Cystadenoma, Mucinous / Q000150:complications / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007322:Instillation, Drug; D010051:Ovarian Neoplasms / Q000150:complications / Q000532:radiotherapy* / Q000601:surgery; D000292:Pelvic Inflammatory Disease / Q000150:complications*; D010529:Peritoneal Cavity; D010710:Phosphates / Q000009:adverse effects* / Q000627:therapeutic use; D010761:Phosphorus Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D011832:Radiation Injuries / Q000209:etiology*; D018714:Radiotherapy, Adjuvant
D017608:Chromium Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; C509369:chromic phosphate